124 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
, customer, distributor, consumer and supplier lists and data, clinical and technical data, operational data, engineering information, invention and technical
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
or confidential information, including trade secrets, know-how, customer, distributor, consumer and supplier lists and data, clinical and technical data
DEFA14A
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
trade secrets, know-how, customer, distributor, consumer and supplier lists and data, clinical and technical data, operational data, engineering
8-K
EX-2.1
IMGN
Immunogen, Inc.
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
trade secrets, know-how, customer, distributor, consumer and supplier lists and data, clinical and technical data, operational data, engineering
8-K
EX-1.1
tjkci2i tun
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
mvjxzoaa
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
6t7bq us44
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-1.1
rvgel9t828hkbnossoa
3 Dec 21
Entry into a Material Definitive Agreement
4:07pm
424B5
7nutsh1uhx 1y6i03
3 Dec 21
Prospectus supplement for primary offering
4:06pm
424B5
406 z3q6zecy
30 Nov 21
Prospectus supplement for primary offering
5:12pm